LifeTech Capital Maintains Bionovo Strong Speculative Buy, Lowers PT

LifeTech Capital maintained its Bionovo

Strong Speculative Buy rating and lowered its Bionovo price target from $7.50 to $5 in a research report published today. In the report, LifeTech Capital states, "Menerba could become the first botanical blockbuster drug which we believe represents an intriguing opportunity for patient investors." Shares of Bionovo were trading at $0.69 at the time of posting, down 12.41% from Tuesday's market close.